HIV drug may overcome proteasome-inhibitor resistance in multiple myelomaMarch 11, 2016Lymphoma & Plasma Cell Disorders
Follicular lymphoma: Quantitative PET/CT measures for detecting bone marrow involvementMarch 10, 2016Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Ibrutinib bodes well for relapsed mantle-cell lymphomaMarch 2, 2016Lymphoma & Plasma Cell DisordersMelanoma
Children’s cancer survival steadily increasingMarch 1, 2016PediatricsCNS/Brain CancerLymphoma & Plasma Cell DisordersPatient & Survivor Care
Ki-67 bests cytology, growth pattern as prognostic factor for MCLFebruary 29, 2016Lymphoma & Plasma Cell Disorders
Panobinostat plus bortezomib and dexamethasone improved outcomes in previously treated multiple myelomaFebruary 19, 2016Lymphoma & Plasma Cell Disorders
Nanoparticles deliver Aurora kinase inhibitor with increased safety and efficacyFebruary 12, 2016Lymphoma & Plasma Cell Disorders
Medicare to cover HSCT in approved clinical trials for myeloma, myelofibrosis, sickle cell diseaseJanuary 28, 2016Practice ManagementLymphoma & Plasma Cell Disorders
Peripheral T-cell lymphoma incidence and survival varies significantly by raceJanuary 25, 2016Lymphoma & Plasma Cell DisordersPreventive Care
Concerning number of HIV-associated Hodgkin lymphoma patients go untreatedJanuary 18, 2016Lymphoma & Plasma Cell Disorders
Making sense of the expanded myeloma treatment landscapeJanuary 13, 2016Lymphoma & Plasma Cell Disorders
Daratumumab clinically active, well tolerated in heavily treated multiple myelomaJanuary 8, 2016Lymphoma & Plasma Cell Disorders
Heavily pretreated myeloma responds to pembrolizumab comboDecember 29, 2015Lymphoma & Plasma Cell Disorders
ASH: First shot across the bow for CAR T cells in multiple myelomaDecember 17, 2015Lymphoma & Plasma Cell Disorders
Pregnancy did not increase Hodgkin lymphoma relapse rateDecember 14, 2015Lymphoma & Plasma Cell DisordersPatient & Survivor Care
